Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences: FDA signs off on home-based protocol fo MS treatment
07:23am, Wednesday, 18'th Oct 2023
Regulators have granted approval for home-based self-administration of Intranasal Foralumab, a treatment developed by Tiziana Life Sciences Ltd (NASDAQ:TLSA). Sign-off by the US Food & Drug Administ
Tiziana Life Sciences stock continues to climb; COO ‘excited' by recent results
01:15pm, Monday, 16'th Oct 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose 8% to $0.86 in midday trading on Monday after the clinical-stage biopharmaceutical company revealed six-month data that showed positive clinical imp
Tiziana Life Sciences reveals positive clinical results for MS patients treated with Foralumab
08:28am, Monday, 16'th Oct 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measur
Tiziana Life Sciences' Matthew Davis discusses significance of latest MS treatment data
04:05am, Monday, 16'th Oct 2023
In an exclusive interview with Thomas Warner from Proactive, Matthew Davis, the chief medical officer and chief operating officer of Tiziana Life Sciences Ltd (NASDAQ:TLSA), discussed the company's la
Tiziana Life Sciences reveals positive PET scan results with Foralumab to treat MS patients
08:34am, Friday, 13'th Oct 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of
Tiziana Life Sciences to present MS treatment at ECTRIMS Annual Congress
09:26am, Wednesday, 11'th Oct 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that a late breaking poster titled, "Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Saf
Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMS
08:16am, Tuesday, 26'th Sep 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has commenced site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
07:00am, Friday, 08'th Sep 2023
NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences highlights publication of promising intranasal foralumab in Alzheimer's study results
09:33am, Wednesday, 06'th Sep 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said a study validating the mechanism of action of its drug candidate intranasal foralumab in Alzheimer's Disease has been published in the prestigious journal
Tiziana Life Sciences investigational therapeutic foralumab in the spotlight at neuroimmunology event
08:31am, Wednesday, 23'rd Aug 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational therapeutic foralumab will be highlighted by its scientific advisory board chairman Dr. Howard Weiner during an oral presentation at th
Tiziana Life Sciences shares skyrocket after FDA greenlights intranasal foralumab for Alzheimer's disease
09:04am, Tuesday, 15'th Aug 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares added almost 55% in pre-market trading on Tuesday after the biotechnology company announced that its Investigational New Drug (IND) application for intra
Tiziana Life Sciences' stock soars 41% premarket after FDA clear path for trial of intranasal treatment for Alzheimer's disease
07:29am, Tuesday, 15'th Aug 2023
Tiziana Life Sciences Ltd.'s stock TLSA soared 41% in premarket trade Tuesday, after the microcap biotech said it has received clearance from Food and Drug Administration for its investigational new d
Tiziana promotes chief medical officer Dr Matthew Davis to chief operating officer
08:16am, Tuesday, 13'th Jun 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has appointed chief medical officer Dr Matthew Davis as its new chief operating officer. With the additional role, Tiziana said Davis will further dri
Tiziana Life Sciences finds promising indicator of MS treatment success
10:59am, Monday, 05'th Jun 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced a significant update regarding non-active secondary progressive multiple sclerosis (SPMS) patients treated with h intranasal foralumab in the company'
Tiziana shares positive findings on intranasal foralumab in treating intracerebral hemorrhage
09:26am, Thursday, 27'th Apr 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported promising in-depth findings on the utility of its lead candidate, intranasal foralumab, which is the only fully human anti-CD3 monoclonal antibody (mAb
